ETH researchers have realised a long-held dream: inspired by an industrial assembly line, they have developed a nanoscale production line for the assembly of biological molecules. https://www.ethz.ch/en/news-and-events/eth-news/news/2014/08/Nanoscale-assembly-line.html
MEDIA RELEASE: Australian Research Council (ARC) Chief Executive Officer (CEO), Professor Aidan Byrne, has today officially opened the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology at Monash University in Melbourne.
Professor Byrne opened the Centre on behalf of the Minister for Education, the Hon. Christopher Pyne MP, and said it would be the focus of bio-nano research activity in Australia.
“Nanomedicines are on the cusp of revolutionising diagnosis and therapy in many diseases; the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology comprises a multi-disciplinary team focused on understanding and controlling the interface of materials with biological systems.
“The expected outcomes through research at this Centre are better diagnostic and therapeutic tools that are designed via an enhanced understanding of the bio-nano interface. rest
WALTHAM, Mass., June 16, 2014 – Alere Inc. (NYSE: ALR), a leading global provider of point-of-care rapid diagnostic and health information solutions, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Alere™ i Influenza A & B test, the first and only molecular test to detect and differentiate influenza A and B virus in less than 15 minutes. …
Molecular testing involves the extraction and analysis of DNA or RNA strands to detect sequences associated with viral and bacterial causes of infections. Alere i Influenza A & B is the first molecular diagnostic test that delivers actionable, lab-accurate results in less than 15 minutes on a user-friendly platform. Unlike polymerase chain reaction (PCR) testing, Alere’s proprietary Molecular. In Minutes™ (MIM) isothermal nucleic acid amplification technology (iNAT) does not require lengthy and complex thermo cycling or DNA purification, and can therefore deliver PCR-caliber results more quickly – and in a broad range of settings. Alere i tests for Strep A, C. difficile, respiratory syncytial virus (RSV) and chlamydia / gonorrhea are currently in development. The complete press release can be found here.
The news media are all over this story but at the same time they miss the relevant facts. For those that want the best information here is the link to the Mayo Clinic Proceedings article entitled Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy.
An antibody and toxin mix has successfully detected and killed HIV-infected cells lurking in the organs and bone marrow of mice that were altered to have a human immune system. The results, reported Thursday in the online journal PLOS Pathogens, offer conceptual proof that a reservoir of HIV-infected cells in organs can sought out and destroyed, a scenario that would potentially end the stalemate between the virus and antiretroviral drug therapies.
NEW YORK (GenomeWeb News) – The New York Genome Center (NYGC) and the University of Buffalo (UB) have received $105 million in state funding to work together in pursuing genomic medicine advances and computational biomedical research, NYGC and UB said today.
The funding, which New York Gov. Andrew Cuomo unveiled in his “State of the State” remarks [January 9th], will provide $55 million to NYGC and $50 million to the University of Buffalo to create the NY Genomic Medicine Network. Rest
A new advance in the use of nanoparticles to deliver medicine or other therapeutics orally is described in a short summary in a Wall Street Journal article or a longer, more detailed news release from MIT. Not surprisingly Professor Robert Langer is an author on the paper appearing in the Nov. 27 online edition of Science Translational Medicine. In a classic example of looking to nature to show the way, the researchers looked at previous work on how babies absorb antibodies from their mothers’ milk, and then built nanoparticles that are selectively passed through the intestinal barrier using protein coats that are recognized by receptor sites in the intestinal lining.
The research was funded by a Koch-Prostate Cancer Foundation Award in Nanotherapeutics; the National Cancer Institute Center of Cancer Nanotechnology Excellence at MIT-Harvard; a National Heart, Lung, and Blood Institute Program of Excellence in Nanotechnology Award; and the National Institute of Biomedical Imaging and Bioengineering.
A number of diseases—including diabetes, Alzheimer’s, and Parkinson’s—are associated with polypeptides that misfold and aggregate into fibrils that further clump together to form plaques. Researchers have now characterized the structure of an intermediate that leads to fibrils in the folding pathway of a polypeptide implicated in type 2 diabetes.
Disrupting formation of the intermediate structure may provide a new target for preventing or treating the disease, which is a growing public health problem. Type 2 diabetes is defined as an inability to produce enough of or respond properly to insulin. Consequently, glucose builds up in the bloodstream. Over time, the condition causes increasingly serious health problems.
In a strategy known as gene therapy, scientists insert engineered DNA into diseased cells in order to treat or kill them. Now, researchers have combined nanotechnology and synthetic biology to create a simple switch to turn on such genes inside cells. They demonstrate that heat generated by magnetic nanoparticles activates the engineered genes, slowing tumor growth in mice (ACS Synth. Biol. 2013). REST